Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Most relevant
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about I-MAB
09:14aI-Mab Seeks Dual Listing on Hong Kong Stock Exchange
MT
08:01aI-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong ..
PR
12/06I MAB : Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlima..
PU
12/03Health Care Stocks Drifting Lower Ahead of Weekend
MT
12/03I-Mab Starts Dosing in US Mid-Stage Combination Trial of Uliledlimab with Atezolizumab ..
MT
12/03I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlim..
PR
12/03I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlim..
CI
11/12I MAB : INDEX TO CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
PU
11/12I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2..
PU
11/12I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Anti..
CI
11/10Health Care Stocks Decline Premarket Wednesday
MT
11/10I-Mab Working With Jumpcan Pharmaceutical to Develop, Commercialize Growth Hormone Ther..
MT
11/10I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
PU
11/09I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2..
PR
11/08I-Mab, Roche Diagnostics Start Collaboration to Develop Companion Diagnostics Services
MT
11/08I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Di..
PR
11/08I-Mab and Roche Diagnostics Announces Strategic Collaboration to Co-Develop Companion D..
CI
11/05I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Ho..
PU
11/04I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Ho..
PU
11/03I-Mab Announces Upcoming Participation at November Conferences
PR
11/02I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Stra..
PU
11/01I-Mab Names John Long CFO
MT
11/01Needham Adjusts Price Target on I-Mab to $85 from $83, Keeps Buy Rating
MT
11/01I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Stra..
PU
11/01I-Mab Appoints Jielun Zhu as Chief Strategy Officer
CI
11/01I-Mab Appoints John Long as Chief Financial Officer
CI
10/26I-Mab Enters Into Partnership With China's Sinopharm to Distribute Its Products
MT
10/26I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its I..
PR
10/25I-MAB : to set up new Translational Medicine and Formulation Research site in San Diego
AQ
10/22I MAB : to Open Translational Medicine Research Site in San Diego
MT
10/22I-MAB : Expands U.S. Footprint with New R&D Site in San Diego
PR
10/22I-Mab Expands U.S. Footprint with New R&D Site in San Diego
CI
10/19I MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PU
10/18I MAB : Gets IND Approval to Conduct Mid-Stage Cancer Drug Trial in China
MT
10/18I-MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PR
10/18I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinat..
CI
10/15I MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PU
10/13I MAB : Completes Patient Enrollment in Phase 3 Study of Multiple Myeloma Therapy
MT
10/13I-MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PR
10/13I-Mab Advances Late-Stage Development of Its Differentiated CD38 Antibody Felzartamab i..
CI
10/05I-MAB : and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at th..
PR
10/05I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at t..
CI
10/04I MAB : Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzopa..
PU
10/01I-MAB : Announces Upcoming Participation at October Conferences
PR
09/30I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzop..
CI
09/29I MAB : Exploring Partnership, Stake Sale to Major Drugmakers
MT
09/28I-Mab Secures Approval to Conduct Phase 2 Trial of Enoblituzumab Combo Therapy for Soli..
MT
09/28I-MAB : Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial..
PR
09/28I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Tria..
CI
09/20I-MAB(NASDAQGM : IMAB) added to FTSE All-World Index
CI
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/13I-MAB : Added to FTSE ESG Index Series
PR
09/02I-MAB : Added to FTSE Russell Global Equity Index Series
PR
09/01I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating
MT
08/31I MAB : H1 Loss Widens
MT
08/31I MAB : Provides Business and Corporate Updates and Reports Financial Results for the Six ..
PU
08/31I-Mab Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021
CI
08/30I-MAB : Announces Upcoming Participation at September Conferences
PR
08/27I MAB : Announces Upcoming Participation at September Conferences
PU
08/20I MAB : Announces Establishment of Environmental, Social and Governance Committee (Form 6-..
PU
08/20I-Mab Announces Committee Appointments
CI
08/19I-MAB : Announces Establishment of Environmental, Social and Governance Committee
PR
08/17I-MAB : to Provide Business and Corporate Updates and Report Financial Results for the Six..
PR
08/12I MAB : Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plon..
PU
08/11I MAB : Says Plonmarlimab Demonstrated Therapeutic Potential in Severe COVID-19
MT
08/11I-MAB : Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plon..
PR
08/11I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of Its GM-CSF Antibody Plo..
CI
08/01I-Mab Biopharma Mulls Dual-Listing on Shanghai Star Board & HKEX
CI
07/30I MAB : Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Trea..
PU
07/30I MAB : Receives FDA Approval to Begin Phase 1 Clinical Trial of Alzheimer's Drug Candidat..
MT
07/30I MAB : Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combina..
PU
07/30I-MAB : Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Trea..
PR
07/30I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Tre..
CI
07/29I MAB : Announces Authorization of a Renewed Stock Repurchase Program by the Company up to..
PU
07/29I-Mab announces an Equity Buyback for $40 million worth of its shares.
CI
1  2  3  4Next